Pancreatic carcinoma (PDAC) carries significant morbidity and mortality and remains one of the most difficult malignancies to treat. Individual patient and tumor factors need to be taken into account to provide an optimal, personalized approach. The following article evaluates the response of pancreatic ductal carcinoma after neoplastic adjuvant therapy

The role of conventional computed tomography (CT) features in assessing response to neoadjuvant therapy for pancreatic ductal adenocarcinoma is limited. Other imaging techniques such as EUS, DWI, PET, and perfusion CT have great potential to assess tumor resectability and predict survival in pancreatic ductal adenocarcinoma after neoadjuvant therapy.